We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy


2C or Not 2C: CYP2C Induction Studies for Successful Preclinical Risk Assessment (Webinar)

Video   May 01, 2021


Webinar Presenters: Becky Campbell, Principal Scientist in Program Oversight, and Andrew G. Taylor, Ph.D., Technical Support Manager for Services


As a part of IND-enabling preclinical drug development studies companies are required to meet regulatory expectations to evaluate the induction potential of their compound for the cytochrome P450 CYP enzymes CYP1A2, 2B6, 2C8, 2C19 and 3A4. While only CYP1A2, 2B6 and 3A4 must be assessed in the initial induction panel, any observed induction of CYP3A4 requires further investigation of induction potential for enzymes in the CYP2C family due to shared activation by the PXR nuclear receptor pathway. This webinar will focus on CYP2C induction and will emphasize when to include CYP2C induction in a study, how to design the study to generate meaningful data and meet the regulatory requirements, what endpoints to measure, and how to interpret results.

Keypoints covered in this webinar include:

- Enzyme Induction studies in DDI risk prediction

- Crosstalk and other mechanistic considerations

- Conditions that warrant 2C investigation

- Regulatory expectations for induction data

- Standard CYP2C induction assay design

- Positive controls

- Appropriate test systems

- Endpoints (mRNA versus activity)

- Efficient planning to anticipate CYP2C inclusion

- Possibility of metabolites masking induction when looking at activity as an endpoint

- How to interpret results

Receive a copy of the slides: https://www.xenotech.com/about/events/2c-or-not-2c-cyp2c-induction-studies-for-successful-preclinical-risk-assessment/

​Questions, comments and requests: https://www.xenotech.com/contact/

​More information on our research services and test systems: https://www.xenotech.com

​Other previously aired webinars: https://www.xenotech.com/access-adme-research-resources/resource-type/webinar/

​Upcoming webinar notifications: https://www.xenotech.com/contact/newsletter-sign-up/

​Request a webinar topic: https://www.xenotech.com/contact/webinar-seminar-request/

About the Presenters:

Becky Campbell, B.S. Principal Scientist in Program Oversight

Rebecca Campbell joined SEKISUI XenoTech in 2001. Prior to joining SEKISUI XenoTech, she obtained her Bachelor of Science in Biology from the University of Central Missouri and studied toxicology and pharmaceutical sciences at the University of Missouri-Kansas City School of Pharmacy. Rebecca has extensive experience in in vitro CYP induction studies, regulatory compliance, and project management. As a Principal Scientist in Scientific Operations, she is responsible for the conduct and oversight of the nonclinical, drug interaction-related contract studies in the Program Oversight Department of SEKISUI XenoTech’s Scientific Division.

Andrew G. Taylor, Ph.D. Manager, Technical Support for Services

Dr. Andrew G. Taylor received his Ph.D. from University of California San Diego, Scripps Institution of Oceanography. He joined SEKISUI XenoTech as a research scientist in 2017, serving as a Study Director in nonclinical drug interaction contract studies compliance with Good Laboratory in Practices (GLP), OECD Principles of GLP, &/or Japan MOHW GLP Standards and specializing in drug transport and drug metabolism studies. He became the Technical Support Manager for services in 2020 and provides valuable guidance to ensure research needs are being met.

More Information

Request Information


Recommended Videos

Breast Cancer Treatment – Prof. Andrew Tutt on the OlympiA Trial


The results of the OlympiA clinical trial, involving ICR researchers, shows giving the drug olaparib for one year to breast cancer patients with inherited BRCA mutations, after they have completed initial treatment, reduced the chance of their breast cancer returning. Professor Andrew Tutt, Head of Breast Cancer Research at the ICR, explains more.


Potential Therapeutic Uses of Cannabinoids With Professor Roger Pertwee


Much of what we know about the cannabis plant and its effects on the human body has only been formally discovered in the past 60 years. A good deal of these pioneering investigations have involved today's Teach Me in 10 guest: Roger Pertwee, an emeritus professor at the University of Aberdeen.


Amersham™ brand ImageQuant™ 800 GxP biomolecular imager – Cytiva


Sensitive, flexible CCD-based imagers designed to support FDA 21 CFR Part 11 EU GMP Annex 11 regulations



Like what you just watched? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free